A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity

PLoS Pathogens

Volumn 10, Issue 4, 2014, Pages

  Qi, Hangfei ^a   Olson, C Anders ^a   Wu, Nicholas C ^b   Ke, Ruian ^b   Loverdo, Claude ^b   Chu, Virginia ^b   Truong, Shawna ^b   Remenyi, Roland ^a   Chen, Zugen ^a   Du, Yushen ^a   Su, Sheng Yao ^c,d   Al Mawsawi, Laith Q ^a   Wu, Ting Ting ^a   Chen, Shu Hua ^c   Lin, Chung Yen ^c   Zhong, Weidong ^e   Lloyd Smith, James O ^b,f   Sun, Ren ^a,b,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF INFORMATION SCIENCE   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; NONSTRUCTURAL PROTEIN 5A; VIRUS RNA; BMS-790052; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE MAPPING; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MUTAGENESIS; NONHUMAN; OUTCOME ASSESSMENT; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN INTERACTION; QUANTITATIVE STUDY; RECOMMENDED DRUG DOSE; REPRODUCTIVE FITNESS; SCORING SYSTEM; SEQUENCE ANALYSIS; VALIDATION STUDY; VIRAL GENETICS; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; CELL LINE; DRUG EFFECTS; GENETICS; HEPACIVIRUS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CELL LINE; DRUG RESISTANCE, VIRAL; GENE EXPRESSION PROFILING; GENETIC FITNESS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84901378315     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004064     Document Type: Article

References (61)

1. Chan M (2011) Antimicrobial resistance: no action today, no cure tomorrow. Atlanta, GA 30333, USA: Center of Disease Control and Prevention.
2. Wu NC, Young AP, Dandekar S, Wijersuriya H, Al-Mawsawi LQ, et al. (2013) Systematic Identification of H274Y Compensatory Mutations in Influenza A Virus Neuraminidase by High-Throughput Screening. Journal of Virology 87: 1193-1199.
3. Maisnier-Patin S, Andersson DI, (2004) Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res Microbiol 155: 360-369.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB, (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
5. Feld JJ, Hoofnagle JH, (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972.
6. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
7. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
8. Robinson M, Tian Y, Delaney WEt, Greenstein AE, (2011) Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Proc Natl Acad Sci U S A 108: 10290-10295.
9. Thompson AJ, Locarnini SA, Beard MR, (2011) Resistance to anti-HCV protease inhibitors. Curr Opin Virol 1: 599-606.
10. Lohmann V, Körner F, Koch J-O, Herian U, Theilmann L, et al. (1999) Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line. Science 285: 110-113.
11. Blight KJ, Kolykhalov AA, Rice CM, (2000) Efficient Initiation of HCV RNA Replication in Cell Culture. Science 290: 1972-1974.
12. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
13. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623-626.
14. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294-9299.
15. De Clercq E, (2012) The race for interferon-free HCV therapies: a snapshot by the spring of 2012. Rev Med Virol.
16. Scheel TK, Rice CM, (2013) Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 19: 837-849.
17. Belda O, Targett-Adams P, (2012) Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Research 170: 1-14.
18. Aghemo A, De Francesco R, (2013) New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 58: 428-438.
19. Lemm JA, O'Boyle D, Liu M, Nower PT, Colonno R, et al. (2010) Identification of Hepatitis C Virus NS5A Inhibitors. Journal of Virology 84: 482-491.
20. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, et al. (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465: 96-100.
21. Tellinghuisen TL, Evans MJ, von Hahn T, You S, Rice CM, (2007) Studying Hepatitis C Virus: Making the Best of a Bad Virus. Journal of Virology 81: 8853-8867.
22. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, et al. (2013) Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proceedings of the National Academy of Sciences 110: 3991-3996.
23. Lee C, Ma H, Hang JQ, Leveque V, Sklan EH, et al. (2011) The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 414: 10-18.
24. Fridell RA, Qiu D, Wang C, Valera L, Gao M, (2010) Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System. Antimicrobial Agents and Chemotherapy 54: 3641-3650.
25. Wang C, Huang H, Valera L, Sun J-H, O'Boyle DR, et al. (2012) Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052. Antimicrobial Agents and Chemotherapy 56: 1350-1358.
26. Wang C, Jia L, Huang H, Qiu D, Valera L, et al. (2012) In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother 56: 1588-1590.
27. Fowler DM, Araya CL, Fleishman SJ, Kellogg EH, Stephany JJ, et al. (2010) High-resolution mapping of protein sequence-function relationships. Nat Meth 7: 741-746.
28. Moya A, Elena SF, Bracho A, Miralles R, Barrio E, (2000) The evolution of RNA viruses: A population genetics view. Proc Natl Acad Sci U S A 97: 6967-6973.
29. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM, (2007) Hepatitis C Virus p7 and NS2 Proteins Are Essential for Production of Infectious Virus. Journal of Virology 81: 8374-8383.
30. Penin Fβ, Brass V, Appel N, Ramboarina S, Montserret R, et al. (2004) Structure and Function of the Membrane Anchor Domain of Hepatitis C Virus Nonstructural Protein 5A. Journal of Biological Chemistry 279: 40835-40843.
31. Elazar M, Cheong KH, Liu P, Greenberg HB, Rice CM, et al. (2003) Amphipathic Helix-Dependent Localization of NS5A Mediates Hepatitis C Virus RNA Replication. Journal of Virology 77: 6055-6061.
32. Song J, Nagano-Fujii M, Wang F, Florese R, Fujita T, et al. (2000) Nuclear localization and intramolecular cleavage of N-terminally deleted NS5A protein of hepatitis C virus. Virus Research 69: 109-117.
33. Cho N-J, Cheong KH, Lee C, Frank CW, Glenn JS, (2007) Binding Dynamics of Hepatitis C Virus' NS5A Amphipathic Peptide to Cell and Model Membranes. Journal of Virology 81: 6682-6689.
34. Brass V, Bieck E, Montserret R, Wolk B, Hellings JA, et al. (2002) An Amino-terminal Amphipathic α-Helix Mediates Membrane Association of the Hepatitis C Virus Nonstructural Protein 5A. Journal of Biological Chemistry 277: 8130-8139.
35. Kay BK, Williamson MP, Sudol M, (2000) The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J 14: 231-241.
36. Adzhubei AA, Sternberg MJ, Makarov AA, (2013) Polyproline-II Helix in Proteins: Structure and Function. J Mol Biol 425: 2100-2132.
37. Tellinghuisen TL, Marcotrigiano J, Rice CM, (2005) Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435: 374-379.
38. Huang L, Hwang J, Sharma SD, Hargittai MRS, Chen Y, et al. (2005) Hepatitis C Virus Nonstructural Protein 5A (NS5A) Is an RNA-binding Protein. Journal of Biological Chemistry 280: 36417-36428.
39. Foster TL, Belyaeva T, Stonehouse NJ, Pearson AR, Harris M, (2010) All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding. J Virol 84: 9267-9277.
40. Hwang J, Huang L, Cordek DG, Vaughan R, Reynolds SL, et al. (2010) Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins. J Virol 84: 12480-12491.
41. Scheel TKH, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J, (2011) Recombinant HCV Variants With NS5A From Genotypes 1'7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-α. Gastroenterology 140: 1032-1042.e1036.
42. Fridell RA, Wang C, Sun J-H, O'Boyle DR, Nower P, et al. (2011) Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations. Hepatology 54: 1924-1935.
43. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, et al. (1998) Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy. Science 282: 103-107.
44. Rong L, Dahari H, Ribeiro RM, Perelson AS, (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2: 30ra32.
45. Ke R, Loverdo C, Qi H, Olson CA, Wu NC, et al. (2013) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. Journal of Antimicrobial Chemotherapy 69: 724-727.
46. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, et al. (2013) 1417 Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (Rbv) In Chronic Hcv Genotype (Gt) 1-Infected Patients Who Previously Failed Telaprevir (Tvr) Or Boceprevir (Boc). Journal of Hepatology 58, Supplement 1: S570.
47. Manns MP, von Hahn T, (2013) Novel therapies for hepatitis C- one pill fits all? Nat Rev Drug Discov 12: 595-610.
48. Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CnN, (2009) Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus. Journal of Virology 83: 4395-4403.
49. Moradpour D, Penin F (2013) Hepatitis C Virus Proteins: From Structure to Function. In: Bartenschlager R, editor. Hepatitis C Virus: From Molecular Virology to Antiviral Therapy. Springer Berlin Heidelberg. pp. 113-142.
50. Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, et al. (2009) Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci U S A 106: 7577-7582.
51. Berger KL, Kelly SM, Jordan TX, Tartell MA, Randall G, (2011) Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J Virol 85: 8870-8883.
52. Lim YS, Hwang SB, (2011) Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation. J Biol Chem 286: 11290-11298.
53. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, et al. (2011) Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9: 32-45.
54. Tai AW, Salloum S, (2011) The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PLoS One 6: e26300.
55. Reiss S, Harak C, Romero-Brey I, Radujkovic D, Klein R, et al. (2013) The Lipid Kinase Phosphatidylinositol-4 Kinase III Alpha Regulates the Phosphorylation Status of Hepatitis C Virus NS5A. PLoS Pathog 9: e1003359.
56. Nettles RE, Gao M, Bifano M, Chung E, Persson A, et al. (2011) Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54: 1956-1965.
57. Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, et al. (2013) Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 57: 2054-2065.
58. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, et al. (2012) Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 12: 671-677.
59. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, et al. (2012) Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366: 216-224.
60. Ribeiro RM, Li H, Wang S, Stoddard MB, Learn GH, et al. (2012) Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 8: e1002881.
61. Rong L, Guedj J, Dahari H, Coffield DJ Jr, Levi M, et al. (2013) Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol 9: e1002959.